Avacta Group (LON:AVCT) Reaches New 12-Month High - What's Next?

Key Points

• Avacta Group's stock price reached a new 52-week high of GBX 75 ($1.01) during trading, with the current price at GBX 70.90 ($0.96).
• Analysts from Peel Hunt have set a target price of GBX 99 for Avacta Group, maintaining a "buy" rating.
• The company reported a quarterly EPS of (4.46) and has a forecasted EPS for the current year of approximately (9.90).

Avacta Group Plc (LON:AVCT - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 75 ($1.01) and last traded at GBX 70.90 ($0.96), with a volume of 9011766 shares trading hands. The stock had previously closed at GBX 70.19 ($0.95).

Analysts Set New Price Targets

Separately, Peel Hunt reiterated a "buy" rating and set a GBX 99 target price on shares of Avacta Group in a research report on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Avacta Group presently has an average rating of "Buy" and a consensus price target of GBX 99.

Avacta Group Price Performance

The firm has a market capitalization of £289.46 million, a PE ratio of -403.99 and a beta of 1.12. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29. The stock's 50 day simple moving average is GBX 53.24 and its two-hundred day simple moving average is GBX 40.84.

Avacta Group (LON:AVCT - Get Free Report) last posted its quarterly earnings results on Tuesday, September 30th. The biotechnology company reported GBX (4.46) EPS for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. On average, sell-side analysts forecast that Avacta Group Plc will post -9.9011833 EPS for the current year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.